Literature DB >> 32185066

Hydroxychloroquine-induced erythema multiforme.

Dimitra Koumaki1, Vasiliki Koumaki2, George Bertsias3, Sotirios Boumpoucheropoulos4, Alexander Katoulis5, Maria Stefanidou1, Orestis Miaris6, George Evangelou1, Kyriaki Zografaki1, Sabine Elke Krueger-Krasagakis1, Konstantinos Krasagakis1.   

Abstract

Hydroxychloroquine is a commonly used medication and rarely may result in development of erythema multiforme. This potential cutaneous side effect should be highlighted in information given to patients prior to hydroxychloroquine commencement.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antimalarials; erythema multiforme; hydroxychloroquine; severe cutaneous adverse drug reactions

Year:  2020        PMID: 32185066      PMCID: PMC7069841          DOI: 10.1002/ccr3.2648

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


CLINICAL IMAGE

A 60‐year‐old Caucasian woman with a past medical history of essential hypertension and chronic obstructive pulmonary disease presented with a 5‐day history of a widespread pruritic, striking erythematous to purple targetoid eruption on her trunk, neck, upper, and lower limbs (Figures 1 and 2). She also complained of fatigue. She had been started on hydroxychloroquine (HCQ) 200 mg twice daily 19 days prior to presentation for arthritis. Histology of a skin biopsy from the left arm revealed interface dermatitis and eosinophil infiltrates. Hydroxychloroquine was discontinued from the day of admission, and the patient was initially started on treatment with intravenous prednisolone 62.5 mg once daily that was gradually reduced over a 6‐week period. At the time of discharge, 4 weeks later, most of the lesions had subsided and after 8 weeks, her skin appeared normal.
Figure 1

Typical targetoid lesions on the right arm

Figure 2

Widespread violaceous to erythematous plaques on the trunk of the patient

Typical targetoid lesions on the right arm Widespread violaceous to erythematous plaques on the trunk of the patient

What is your diagnosis?

Hydroxychloroquine‐induced erythema multiforme.

DISCUSSION

Severe cutaneous reactions to hydroxychloroquine are uncommon1, 2 However, as in this case, drug hypersensitivity reactions often manifest in skin. Because of the extensive use of HCQ in the treatment of numerous dermatologic and rheumatologic conditions, because no specific therapy is available, and because correct diagnosis generally leads to spontaneous resolution once the causative drug is withdrawn, clinicians should keep the possibility of this rare but severe, extensive, and acute reaction in mind.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

DK: did substantial contributions to conception and design, acquisition, analysis, and interpretation of data, was involved in drafting the manuscript and revising it critically for important intellectual content, and gave final approval of the version to be published. VK, GB, SB, AK, MS, OM, GE, KZ, SEKK, and KK: were involved in drafting the manuscript, revising it critically for important intellectual content, and gave final approval of the version to be published.

CONSENT STATEMENT

Informed written consent was obtained from the patient for publication of her images.
  4 in total

Review 1.  Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Authors:  Alina Dima; Ciprian Jurcut; François Chasset; Renaud Felten; Laurent Arnaud
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-14       Impact factor: 5.346

2.  Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2.

Authors:  H Janah; A Zinebi; J Elbenaye
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-04       Impact factor: 9.228

Review 3.  All about COVID-19 in brief.

Authors:  A Naserghandi; S F Allameh; R Saffarpour
Journal:  New Microbes New Infect       Date:  2020-04-13

4.  Generalized exanthema due to hydroxychloroquine during COVID-19 prophylaxis.

Authors:  Ömer Kutlu; Pınar Özdemir Çetinkaya; Habibullah Aktaş; Ahmet Metin
Journal:  Int J Clin Pract       Date:  2021-02       Impact factor: 3.149

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.